• In Europe, statistically every second person develops cancer at some point in their life – a dramatic medical challenge with enormous social and economic implications. Many types of cancer, including aggressive forms such as lung and pancreatic cancer, are still not treatable with targeted therapies. The demand for innovative and effective treatment approaches is therefore high – and continues to grow.

• PRAMOMOLECULAR addresses this unmet medical need with a proprietary gene-silencing platform that specifically blocks the expression of cancer-relevant proteins. In preclinical models, this approach was able to significantly reduce tumor growth and, in some cases, even achieve tumor regression – clear evidence of its therapeutic potential.

• he technology enables rapid, modular development of novel drug candidates targeting multiple oncogenic targets – both as monotherapy and in combination with existing treatment regimens. PRAMOMOLECULAR collaborates closely with leading oncologists as well as established pharmaceutical and biotech companies to leverage synergies and efficiently advance translation into the clinic.

• As one of the world’s most promising biotech startups in the field of oncology, PRAMOMOLECULAR is in a strategically attractive position. Preparations are currently underway for advanced preclinical studies, with the goal of initiating the first clinical Phase I study in 2027.

• Investors benefit from a clearly differentiated mechanism of action, a scalable platform approach, and a growing market with high medical need. PRAMOMOLECULAR thus offers an exceptional opportunity to participate early in the development of a potentially transformative therapy.

Notice pursuant to Section 12 (2) of the German Investment Assets Act :
The described investment involves significant risks and may result in the total loss of your invested capital. The projected return is not guaranteed and may be lower than expected!

Would you like to stay updated on news from PRAMO?

Or feel free to contact us if you have any questions.